Acromegaly is a rare endocrine condition caused by hypersecretion of human growth hormone (GH) that results in elevated circulating levels of GH and insulin-like growth factor-1 (IGF-1). Opko Biologics Ltd. has presented data on the development and characterization of OPKO-8801001, a long-acting human GH receptor (GHR) antagonist with prolonged systemic exposure and pharmacological activity designed for subcutaneous administration.